You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and accompanying notes included in this quarterly report and our audited financial statements and Management's Discussion and Analysis of Financial Condition and Results of Operations included in our Annual Report on Form 10-K for the year ended December 31, 2007, which is on file with the SEC. In addition to historical information, the following discussion contains forward-looking statements that involve risks, uncertainties and assumptions. Our actual results, performance or experience could differ materially from those indicated by the forward-looking statements due to various important factors, risks and uncertainties, including, but not limited to, those set forth under "Cautionary Note Regarding Forward-Looking Statements" in Part I of this quarterly report and under "Risk Factors" in Item 1A of Part I of our Annual Report on Form 10-K for the year ended December 31, 2007 and other filings that we make with the SEC.

Overview

Background

We are a biopharmaceutical company engaged in the design, discovery and development of NNR Therapeutics, a new class of drugs for the treatment of multiple diseases and disorders of the central nervous system. Our NNR Therapeutics selectively target a class of receptors known as neuronal nicotinic receptors, or NNRs. We currently have clinical-stage product candidates in the therapeutic areas of cognitive impairment, depression and anxiety, and pain. We also have preclinical programs focused in smoking cessation, pain, obesity, addiction, Parkinson's disease and inflammation. We have a cognition-focused collaboration with AstraZeneca and a strategic alliance with GlaxoSmithKline.

Our lead product candidate is a novel small molecule that we have historically referred to as TC-1734 and that AstraZeneca refers to as AZD3480. AZD3480 (TC-1734) modulates the activity of the †4ß2 NNR. In December 2005, we entered into a collaborative research and license agreement with AstraZeneca AB for the development and worldwide commercialization of AZD3480 (TC-1734) as a treatment for Alzheimer's disease, cognitive dysfunction in schizophrenia and potentially other conditions characterized by cognitive impairment such as attention deficit hyperactivity disorder, or ADHD, age associated memory impairment, or AAMI, and mild cognitive impairment, or MCI.

AstraZeneca has completed a Phase 2b clinical trial of AZD3480 (TC-1734) in mild to moderate Alzheimer's disease, known as the Sirocco trial, and is conducting an ongoing Phase 2b clinical trial in cognitive dysfunction in schizophrenia, known as the HALO trial. AZD3480 (TC-1734) is also currently being studied in an exploratory Phase 2 clinical trial in adults with ADHD. We announced top-line results from the Sirocco trial in September 2008. Top-line results from the HALO trial are expected in December 2008. A decision by AstraZeneca whether to conduct further development of AZD3480 (TC-1734) for any one or more of mild to moderate Alzheimer's disease, cognitive dysfunction in schizophrenia and ADHD is expected by the end of the year, following availability of top-line results from the HALO trial.

We and AstraZeneca are conducting a preclinical research collaboration under our agreement that is designed to discover and develop additional compounds that, like AZD3480 (TC-1734), act on the †4ß2 NNR as treatments for conditions characterized by cognitive impairment. AstraZeneca pays us research fees, based on a reimbursement rate specified under the agreement, for research services rendered in the preclinical research collaboration, subject to specified limits. The research term began in January 2006 and has a planned term of four years.

In July 2007, we entered into a product development and commercialization agreement with SmithKline Beecham Corporation, doing business as GlaxoSmithKline, and Glaxo Group Limited. SmithKline Beecham Corporation and Glaxo Group Limited are referred to together in this quarterly report as GlaxoSmithKline. The agreement sets forth the terms of an alliance designed to discover, develop and market product candidates that selectively target specified NNR subtypes in five therapeutic focus areas: smoking cessation, pain, obesity, addiction and Parkinson's disease.

Our other clinical-stage product candidates, in addition to AZD3480 (TC-1734), are described below.

• TC-5619. TC-5619 is a novel small molecule that we plan to develop for cognitive dysfunction in schizophrenia and potentially one or more other conditions characterized by cognitive impairment. TC-5619 modulates the activity of the †7 NNR. We have completed dosing in a Phase 1 multiple rising dose clinical trial of TC-5619. Following our completion of Phase 1 clinical development and a Phase 2 clinical proof of concept trial of TC-5619, AstraZeneca has the right to license TC-5619 for schizophrenia and various conditions characterized by cognitive impairment on terms specified in our agreement.

• TC-5214. TC-5214 is a product candidate that we are developing as an augmentation therapy for major depressive disorder, or MDD. TC-5214, which is the S(+) enantiomer of mecamylamine hydrochloride, inhibits the activity of various NNR subtypes, including the †4ß2 NNR. We initiated a Phase 2b clinical trial of TC-5214 for MDD in the third quarter of 2008.

• TC-6499. TC-6499 is novel small molecule that we plan to develop as a treatment for neuropathic pain. TC-6499 modulates the activity of the †4ß2 NNR. We initiated a Phase 1 multiple rising dose clinical trial in the third quarter of 2008 and expect to complete the trial by the end of 2008. TC-6499 is subject to a contingent future option of GlaxoSmithKline under the terms of our alliance.

• TC-2216. Our depression and anxiety program also includes the novel small molecule TC-2216. TC-2216 inhibits the activity of the † 4ß2 NNR. We have completed a Phase 1 single rising dose clinical trial of this product candidate. We may in the future elect to develop one of the enantiomers of TC-2216 in lieu of further development of TC-2216. However, based on our development of TC-5214 and our current budget management plans, we are not conducting further clinical development of TC-2216 or either of its enantiomers in 2008 and have no current plan to conduct further clinical development in 2009.

We trace our scientific lineage to a research program initiated by R.J. Reynolds Tobacco Company in 1982 to study the activity and effects of nicotine in the body and the function of nicotinic receptors. We were incorporated in 1997 as a wholly owned subsidiary of RJR. In August 2000, we became an independent company when we issued and sold stock to venture capital investors. Since our inception, we have had limited revenue from product sales and have funded our operations principally through the sale of equity securities, revenue from collaboration agreements and grants and equipment and building lease incentive financing. We have devoted substantially all of our resources to the discovery and development of our product candidates and technologies, including the design, conduct and management of preclinical and clinical studies and related manufacturing, regulatory and clinical affairs, as well as intellectual property prosecution.

We generated net income for the fourth quarter and year ended December 31, 2006 due primarily to the recognition of revenue derived under our agreement with AstraZeneca. Except for these periods, we have never been profitable. As of September 30, 2008, we had an accumulated deficit of $184.5 million. We expect to incur substantial losses for the foreseeable future as we expand our clinical trial activity, as our clinical-stage and preclinical product candidates advance through the development cycle, as we progress our programs in the therapeutic focus areas of our alliance with GlaxoSmithKline and our preclinical research collaboration with AstraZeneca and as we invest in additional product opportunities and research programs and expand our research and development infrastructure. Clinical trials and preclinical studies are time-consuming, expensive and may never yield a product that will generate revenue.

We believe that period-to-period comparisons of our results of operations are not meaningful and should not be relied upon as indicative of our future performance.

Revenue

As of September 30, 2008, we had received $32.2 million in aggregate upfront fees and milestone payments and had recognized $19.6 million in collaboration research and development revenue for preclinical research services under our collaboration agreement with AstraZeneca. As of September 30, 2008, we had also received $41.5 million in aggregate payments under our alliance agreement with GlaxoSmithKline.

We acquired rights to Inversine®, which is our only product approved by the U.S. Food and Drug Administration, or FDA, for marketing, in August 2002. Inversine is approved for the management of moderately severe to severe essential hypertension and in uncomplicated cases of malignant hypertension, which are high blood pressure disorders. However, we believe that Inversine is prescribed predominantly for the treatment of neuropsychiatric disorders, such as Tourette's syndrome, autism and bipolar disorder. Sales of Inversine generated net revenue of $164,000 and $101,000 for the three months ended September 30, 2008 and 2007, respectively, and $551,000 and $446,000 for the nine months ended September 30, 2008 and 2007, respectively. At the beginning of 2008, we instituted a 62% price increase for Inversine to help offset the impact of increased cost of product sales resulting from FDA product and establishment fees and have experienced decreased sales volume in both the three and nine months ended September 30, 2008. We do not anticipate any significant increase in the volume of Inversine sales. We do not have or use a sales force or promote Inversine.

From time to time we seek and are awarded grants or work to be performed under grants awarded to third-party collaborators from which we derive revenue. As of September 30, 2008, we are a named subcontractor under a grant awarded to The California Institute of Technology by the National Institute on Drug Abuse, or NIDA, part of the National Institutes of Health, to fund research on innovative NNR-based approaches to the development of therapies for smoking cessation. We expect to receive approximately $1.1 million in the aggregate over a five-year period that began in July 2006 in connection with the NIDA grant. Funding for awards under federal grant programs is subject to the availability of funds as determined annually in the federal appropriations process.

A substantial portion of our revenue depends on the conduct of research and the successful achievement of milestone events in the development of AZD3480 (TC-1734) under our agreement with AstraZeneca, whether AstraZeneca elects to license TC-5619 following our completion of Phase 1 clinical development and a Phase 2 clinical proof of concept trial, and on the successful achievement of milestone events under our agreement with GlaxoSmithKline in the development of TC-6499 and in the five therapeutic focus areas of our alliance. Our revenue may vary substantially from quarter to quarter and year to year.

Research and Development Expenses

Since our inception, we have focused our activities on our drug discovery and development programs. We record research and development expenses as they are incurred. Research and development expenses represented approximately 87% and 82% of our total operating expenses for the three months ended September 30, 2008 and 2007, respectively, and 85% and 79% of our total operating expenses for the nine months ended September 30, 2008 and 2007, respectively.

Under the terms of our collaboration agreement, AstraZeneca is responsible for substantially all development costs for AZD3480 (TC-1734), except for costs associated with the conduct of the ongoing Phase 2 clinical trial of AZD3480 (TC-1734) in adults with ADHD. The following table shows, for the periods presented, total amounts that we incurred for third-party services in connection with preclinical studies, pharmaceutical development, clinical supplies and clinical trials, as applicable for our most advanced product candidates:

                                   Three months ended       Nine months ended
                                     September 30,            September 30,
                                    2008         2007        2008        2007
             Product Candidate       (in thousands)          (in thousands)
             AZD3480 (TC-1734)   $       85    $     -    $      220    $    -
             TC-5619                    731         378        2,367      1,462
             TC-5214                  1,288       1,306        3,158      2,957
             TC-6499                  1,125         393        1,957      1,019
             TC-2216                     47         591          566      1,069

                                 $    3,276    $  2,668   $    8,268    $ 6,507

The reported amounts for TC-2216 for both of the 2008 periods include costs with respect to non-clinical studies conducted to characterize TC-2216 and its constituent enantiomers further. The reported amount for TC-2216 for the nine months ended September 30, 2008 also includes costs with respect to our completed Phase 1 single rising dose clinical trial.

In December 2007, we announced that TC-2696, a product candidate for acute post-operative pain, did not meet the primary endpoints in a Phase 2 clinical trial in third molar extraction patients. We have no current plans to conduct further clinical development of TC-2696. We incurred expenses for third-party services in connection with the development of TC-2696 of $429,000 and $981,000 for the three and nine months ended September 30, 2007. We have not incurred any expenses in connection with the development of TC-2696 for the comparable 2008 periods.

We utilize our research and development personnel and infrastructure resources across several programs. We currently have clinical, preclinical and early research programs, and many of our costs are not specifically attributable to a single program. Instead, these costs are directed to broadly applicable research efforts. Accordingly, we cannot state precisely our total costs incurred on a program-by-program basis.

We have not received FDA or foreign regulatory marketing approval for any of our product candidates that are in development. Our current and future expenditures on preclinical and clinical development programs are subject to numerous uncertainties in timing and cost to completion. In particular, our strategy includes entering into alliances and collaborations with third parties to participate in the development and commercialization of some of our product candidates. Where a third party has responsibility for or authority over preclinical or clinical development of a particular product candidate, the estimated completion date is largely under control of that third party and not under our control. We cannot forecast with any degree of certainty whether AstraZeneca or GlaxoSmithKline will exercise any options to license particular product candidates that become exercisable under the terms of our respective agreements, which of our product candidates will be subject to future alliances or collaborations or how such arrangements would affect our development plans or capital requirements. Because of these uncertainties, and because of the numerous uncertainties related to clinical trials and related activities, we are unable to determine the duration and completion costs of our research and development programs or whether or when we will generate revenue from the commercialization and sale of any of our product candidates in development.

General and Administrative Expenses

General and administrative expenses consist principally of salaries and other related costs for personnel in executive, finance, accounting, business development, legal and human resource functions. Other general and administrative expenses include expenses associated with stock options and other stock-based compensation granted to personnel in those functions, facility costs not otherwise included in research and development expenses, patent-related costs, insurance costs and professional fees for consulting, legal, accounting and public and investor relations services.

Income Taxes

We generated net income for the fourth quarter and year ended December 31, 2006 due primarily to the recognition of revenue derived under our agreement with AstraZeneca. We incurred net operating losses for each other period since inception and consequently have not paid federal, state or foreign income taxes in any period. As of September 30, 2008, we had net operating loss carryforwards of $113.6 million for each of federal and state income tax purposes. We also had $3.9 million in research and development federal income tax credits as of September 30, 2008. The federal net operating loss carryforwards begin to expire in 2020. The state net operating loss carryforwards begin to expire in 2015. The research and development tax credits begin to expire in

2021. Utilization of the net operating loss carryforwards and credits may be subject to a substantial annual limitation due to ownership change limitations provided by Section 382 of the Internal Revenue Code of 1986, as amended, and similar state provisions. When an ownership change, as defined by Section 382, occurs, an annual limitation is imposed on a company's use of net operating loss and credit carryforwards attributable to periods before the change. As a result of a series of stock issuances, we had such an ownership change in November 2002. Consequently, an annual limitation is imposed on our use of net operating loss and credit carryforwards that are attributable to periods before November 2002 and a portion of the net operating loss carryforwards described above may potentially not be usable by us. We could experience additional ownership changes in the future. For financial reporting purposes, we have recorded a valuation allowance to fully offset the deferred tax asset related to these carryforwards because realization of the benefit is uncertain.

Critical Accounting Policies and Estimates

Our management's discussion and analysis of our financial condition and results of operations are based on our unaudited financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses. On an ongoing basis, we evaluate these estimates and judgments. We base our estimates on historical experience and on various assumptions that we believe to be reasonable under the circumstances. These estimates and assumptions form the basis for making judgments about the carrying values of assets and liabilities and the recording of revenues and expenses that are not readily apparent from other sources. Actual results and experiences may differ materially from these estimates. In addition, our reported financial condition and results of operations could vary if new accounting standards are enacted that are applicable to our business.

Our significant accounting policies are described in Note 2 to our audited financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2007 and in the notes to our financial statements included in this quarterly report. We believe that our accounting policies relating to revenue recognition, accrued expenses and stock-based compensation are the most critical to understanding and evaluating our reported financial results. We have identified these policies as critical because they are important to the presentation of our financial condition and results of operations and require us to make judgments and estimates on matters that are inherently uncertain and may change in future periods. These policies are described under the heading "Management's Discussion and Analysis of Financial Condition and Results of Operations - Critical Accounting Policies and Estimates" in our Annual Report on Form 10-K for the year ended December 31, 2007.

Results of Operations

Three Months ended September 30, 2008 and 2007

Net Operating Revenues

Net operating revenues increased by $1.0 million to $4.1 million for the three months ended September 30, 2008, from $3.1 million for the comparable three-month period in 2007. The higher net operating revenues were principally attributable to an increase of $586,000 in milestones and license fees from collaborations revenue from AstraZeneca and GlaxoSmithKline to $1.6 million for

the 2008 period, from $1.0 for the 2007 period, and to an increase of $361,000 in collaboration research and development revenue to $2.4 million for the 2008 period, from $2.0 million for the 2007 period. The increase in milestones and license fees from collaborations revenue for the 2008 period reflects the recognition of $1.1 million of deferred license fee revenue from payments received from GlaxoSmithKline in July 2007 and from GlaxoSmithKline and AstraZeneca in the fourth quarter of 2007, as compared to $471,000 recognized during the 2007 period. The increase in collaboration research and development revenue for the 2008 period reflects additional services rendered by us in our preclinical research collaboration with AstraZeneca as additional compounds were identified in the collaboration and existing compounds progressed into more advanced stages of research. Based on progress made to date in our preclinical research collaboration with AstraZeneca and our current research plans, we expect collaboration research and development revenue to decrease in 2009, which is the last year planned for the preclinical research collaboration with AstraZeneca.

Research and Development Expenses

Research and development expenses increased by $1.3 million to $10.7 million for the three months ended September 30, 2008, from $9.4 million for the comparable three-month period in 2007. The higher research and development expenses were principally attributable to an increase of $1.2 million in costs for third-party preclinical research and development services incurred primarily in connection with our research collaboration with AstraZeneca and programs in the therapeutic focus areas of our alliance with GlaxoSmithKline to $1.3 million for the 2008 period, from $139,000 for the 2007 period. The higher research and development expenses also reflect an increase of $1.2 million in costs for third-party research and development services incurred in connection with AZD3480 (TC-1734), TC-5619 and TC-6499 to $1.9 million for the 2008 period, from $771,000 for the 2007 period, partially offset by reduced spending of $992,000 for TC-2216 and TC-2696. The higher expenses for TC-5619 and TC-6499 reflect the conduct of later stage clinical trials in the 2008 period as compared to the 2007 period and the expenses for AZD3480 (TC-1734) reflect our funding of the exploratory Phase 2 clinical trial in adults with ADHD initiated in the second quarter of 2008. Research and development expenses for third-party services in connection with TC-5214 were substantially the same for both three-month periods.

We anticipate our research and development expenses for the fourth quarter of 2008 will be higher than our research and development expenses for any of the first three quarters of 2008 as a result of expected costs associated with our ongoing Phase 2b clinical trial of TC-5214, our ongoing Phase 2 clinical trial of AZD3480 (TC-1734) in adults with ADHD, our ongoing Phase 1 clinical trials of TC-5619 and TC-6499 and increased activity in connection with our preclinical programs, including those in the therapeutic focus areas of our alliance with GlaxoSmithKline.

General and Administrative Expenses

General and administrative expenses decreased by $523,000 to $1.4 million for the three- month period ended September 30, 2008, from $1.9 million for the comparable three-month period in 2007. The decrease for the 2008 period was principally attributable to a reduction of $355,000 in compensation-related expenses, primarily as a result of reduced accrual for employee bonuses, and a reduction of $187,000 in patent-related expenses, which reflects differences in the timing of prosecution of foreign patent applications between 2008 and 2007.

Interest Income

Interest income decreased by $502,000 to $579,000 for the three months ended September 30, 2008, from $1.1 million for the comparable three-month period in 2007. The decrease was primarily attributable to lower short-term interest rates, partially offset by a higher average cash and investment balance during the 2008 period.

Interest Expense

Interest expense increased by $17,000 to $65,000 for the three months ended September 30, 2008, from $48,000 for the comparable three-month period in 2007. The increase was attributable to greater indebtedness under our loan facilities. In particular, we borrowed $4.8 million in March 2008 pursuant to a loan agreement that we entered into with a bank. We used $1.7 million of the proceeds to repay a portion of an existing loan facility, resulting in a net increase in indebtedness under our loan facilities of $3.6 million.

Nine Months ended September 30, 2008 and 2007

Net Operating Revenues

Net operating revenues increased by $5.6 million to $13.6 million for the nine months ended September 30, 2008, from $8.0 million for the comparable nine-month period in 2007. The higher net operating revenues were principally attributable to an increase of $3.4 million in milestones and license fees from collaborations revenue from AstraZeneca and GlaxoSmithKline to $5.6 million for the 2008 period, from $2.2 million for the 2007 period, and to an increase of $2.0 million in collaboration research and development revenue to $7.2 million for the 2008 period, from $5.2 million for the 2007 period. The increase in milestones and license fees from collaborations revenue for the 2008 period reflects the recognition of $3.2 million of deferred license fee revenue from payments received from GlaxoSmithKline in July 2007 and from GlaxoSmithKline and AstraZeneca in the fourth quarter of 2007, an increase of $2.7 million over the 2007 period, as well as the achievement of milestone events related to progress in our smoking cessation program under our agreement with GlaxoSmithKline and to the progression of a product candidate in the preclinical research collaboration under our agreement with AstraZeneca, which resulted in an aggregate of $700,000 in payments to us. The increase in collaboration research and development revenue for the 2008 period reflects additional services rendered by us in the preclinical research collaboration with AstraZeneca as additional compounds were . . .